Regulation of chemokine gene expression by hypoxia via cooperative activation of NF-kappaB and histone deacetylase.

Hypoxia is a microenvironmental factor frequently associated with tumors and inflammation. This study addresses the question of how hypoxia modulates the basal and IL-1 beta-induced production of cytokines and aims to identify the underlying mechanism of hypoxic transcriptional repression. We found that despite the similarities of the promoter structures of IL-8 and MCP-1, these chemokines were differently regulated by hypoxia (an increase in IL-8, but a decrease in MCP-1 mRNA and protein expression). Such differences were not observed in a reporter gene assay, in which both of the promoters were activated by hypoxia. The difference in the response to hypoxia between MCP-1 expression and the promoter assay was not due to mRNA instability. Using proteosome inhibitor MG132 and I kappaB overexpression we demonstrated that an NF-kappaB-dependent mechanism was involved in both the activation of IL-8 and the repression of MCP-1 mRNA expression in response to hypoxia. The histone deacetylase inhibitor Trihostatin A abolished the inhibitory actions of hypoxia on IL-1 beta-induced MCP-1 gene expression. Furthermore, hypoxia induced histone deacetylase activity in the nuclear extracts. Although stimulation with IL-1 beta and/or hypoxia increased the acetylation of histones H3 and H4 in the presence of Trihostatin A, histone acetylation remained unchanged when the cells were treated without histone deacetylase inhibitor. Collectively, our findings suggest that transiently transfected promoters are not subject to the same NF-kappaB regulatory mechanisms as their chromatinized counterparts. NF-kappaB, activated by hypoxia, can act as a transcriptional repressor via a mechanism that involves deacetylation of histones.

Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.

Increasing evidence points to a link between histone deacetylases (HDACs) and tumorigenesis. Although several HDAC inhibitors have been tested in clinical trials for cancer therapies, the mechanisms of HDAC activation in tumors remain unknown. In this study, we investigated the pathway of HDAC activation in the context of hypoxia and inflammation, common features of solid tumors. In HeLa cells, hypoxia was a more potent activator of HDAC than IL-1beta. As HDAC protein expression did not change during treatment, we hypothesized that hypoxia regulated HDAC activity through post-translational modification. We observed that hypoxia induced HDAC1 and HDAC2 protein phosphorylation both in the presence and absence of IL-1beta. Using TBB, an inhibitor of protein kinase CK2, we showed that CK2 was required for hypoxia-induced HDAC activation. We also observed that CK2 activity was induced by hypoxia but not by IL-1beta alone. While CK2beta subunits were retained in the cytoplasm upon hypoxic treatment, CK2alpha and CK2alpha' subunits were shuttled to the nucleus, where HDAC1 and HDAC2 are predominantly localized. Knockdown of catalytic and regulatory subunits of CK2 revealed that formation of heterotetramic complex was not required for HDAC phosphorylation. von Hippel-Lindau protein (pVHL) inactivation and hypoxia inducible factor-1alpha (HIF-1alpha) activation are associated with tumor growth and vasculogenesis. Use of Apicidin (an HDAC inhibitor) and TBB revealed that CK2-dependent HDAC activation contributed to pVHL downregulation and HIF-1alpha stabilization under hypoxia. Our findings that CK2 may be a key mediator for HDAC activation under hypoxia support the future application of CK2 inhibitors in cancer therapy.